Returns to Pharmaceutical Innovation in the Market for Oral Chemotherapy in Response to Insurance Coverage Expansion
NBER Working Paper No. 23842
---- Acknowledgments ----
Caroline Bennette was supported by an institutional mentored career development award from the Agency for Healthcare Research and Quality (PI: Sean Sullivan; No. K12HS022982). Dr. Bennette was also supported by a grant from the Laura and John Arnold Foundation (PI: Peter Bach). We are grateful for comments on earlier versions of this work from seminar participants at the University of Washington and the Vancouver Health Economics Meeting. Opinions expressed are the authors’ alone and do not reflect those of the University of Washington, NBER, Flatiron Health, the Agency for Healthcare Research and Quality or the Memorial Sloan Kettering Cancer Center. NBER working papers are circulated for discussion and comment purposes. They have not been peer reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.